This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Ostrowski PJ, Tatton-Brown K. Tatton-Brown-Rahman syndrome. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/.
Tatton-Brown K, Seal S, Ruark E, Harmer J, Ramsay E, Del Vecchio Duarte S, et al. Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nat Genet. 2014;46:385–8.
Tatton-Brown K, Zachariou A, Loveday C, Renwick A, Mahamdallie S, Aksglaede L, et al. The Tatton-Brown-Rahman syndrome: a clinical study of 55 individuals with de novo constitutive DNMT3A variants. Wellcome Open Res. 2018;3:46.
Lemire G, Gauthier J, Soucy JF, Delrue MA. A case of familial transmission of the newly described DNMT3A-Overgrowth Syndrome. Am J Med Genet Part A. 2017;173:1887–90.
Cecchi AC, Haidar A, Marin I, Kwartler CS, Prakash SK, Milewicz DM. Aortic root dilatation and dilated cardiomyopathy in an adult with Tatton-Brown-Rahman syndrome. Am J Med Genet Part A. 2022;188:628–34.
Tovy A, Rosas C, Gaikwad AS, Medrano G, Zhang L, Reyes JM, et al. Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome. Haematologica. 2022;107:887–98.
Jeffries AR, Maroofian R, Salter CG, Chioza BA, Cross HE, Patton MA, et al. Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging. Genome Res. 2019;29:1057–66.
Aref-Eshghi E, Kerkhof J, Pedro VP, Groupe DI France, Barat-Houari M, Ruiz-Pallares N, et al. Evaluation of DNA methylation episignatures for diagnosis and phenotype correlations in 42 Mendelian neurodevelopmental disorders. Am J Med Genet. 2020;106:356–70.
Kerkhof J, Squeo GM, McConkey H, Levy MA, Piemontese MR, Castori M, et al. DNA methylation episignature testing improves molecular diagnosis of Mendelian chromatinopathies. Genet Med. 2022;24:51–60.
Ghaoui R, Ha TT, Kerkhof J, McConkey H, Gao S, Babic M, et al. Expanding the phenotype of DNMT3A as a cause a congenital myopathy with rhabdomyolysis. Neuromuscul Disord. 2023;33:484–9.
We thank the patients and their families for participating in this study.
No funding or financial assistance was received in support of the study.
The authors declare no competing interests.
Informed consent for trio-based whole exome sequencing and for the publication of clinical data and photographs were obtained from the patients. Ethical approval was not required by our ethics committee, given the fact that this research concerns a case report.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kumps, C., D’haenens, E., Kerkhof, J. et al. Methylation signatures in clinically variable syndromic disorders: a familial DNMT3A variant in two adults with Tatton-Brown–Rahman syndrome. Eur J Hum Genet 31, 1350–1354 (2023). https://doi.org/10.1038/s41431-023-01459-w